By revealing that ELF4 could alleviate intestinal inflammation through activating IL1RN transcription, suppressing inflammatory TH17 cell activity, and inducing macrophage M2 polarization, the study offers a potential therapeutic target for IBD. Here, ELF4 is linked to inflammatory bowel disease.